Merck: This Cancer-Drug Powerhouse Could Be a Core Dividend
A dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
Starting your investment journey? Learn what to watch out for as a new investor to avoid common pitfalls and make wise choices.
27,695 articlesA dividend-focused investor might overlook Merck at first glance. Yet this cancer‑drug powerhouse blends steady cash ...
Today’s trading session spotlighted PayPal as takeover rumors circulated, lifting the stock while the broader market ...
Digimarc's Q1 2026 results shed light on its trajectory for the year. This analysis breaks down revenue, cash flow, a...
A 740,000-vehicle recall casts a long shadow over Ford's rebound story, threatening brand trust and investor sentimen...
In 2025, a surprising shift reshaped the starter-home landscape: flippers supplied more starter homes than traditiona...
Energy markets are heating up as majors chase bolt-ons and long-life assets. Here are three smaller firms primed for ...
The question 'Is corp. stock seriously undervalued?' isn’t easy to answer for FMC. A mix of debt, patent risk, and a ...
A sharp move in bicara stock 50% has spotlighted a bold biotech bet that now accounts for nearly a third of one inves...
Oracle’s massive debt problem isn’t just a headline. In this guide, we break down the debt load, its possible payback...
When the chips slide, investors hunt for the best pick. This guide weighs Marvell and Broadcom as the market cools, o...
Robinhood shares jumped on regulatory news and improving sentiment for retail platforms, even as crypto markets faced...
A legendary investor bets on a familiar retailer. This guide shows how to spot similar bargains, evaluate their upsid...